Phase II trial of ISIS 353512.

Trial Profile

Phase II trial of ISIS 353512.

Planning
Phase of Trial: Phase II

Latest Information Update: 06 May 2011

At a glance

  • Drugs ISIS 353512 (Primary)
  • Indications Cancer; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 06 May 2011 Isis Pharmaceuticals has reported that it is ready to initiate this trial.
    • 25 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top